The Native Antigen Company: at the starting line for emerging diseases
In this video from ELRIG 2022, Gareth Humphries, Scientific Sales Specialist at The Native Antigen Company, relates the fascinating story of how The Native Antigen Company were able to rapidly develop SARS-CoV-2 spike proteins for use in research at the beginning of the COVID-19 pandemic.
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
